Nicholas Haining is a physician-scientist, immunologist and drug developer. He received his undergraduate and medical degree from Oxford University and completed his medical training in Pediatrics at Children's Hospital, Boston, and subsequently in Pediatric Hematology/Oncology at Dana-Farber Cancer Institute. As an Associate Professor of Pediatrics at Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT his lab defined some of the key transcriptional and epigenetic regulators of T cell exhaustion and used in vivo genetic screens to identify immune vulnerabilities of cancer cells in mouse models. His clinical expertise is in hematopoietic stem cell transplantation, and he attended on the bone marrow transplant service at Children’s Hospital, Boston for almost twenty years. Most recently, he served as Vice-President, Discovery Oncology and Immunology at Merck Research Laboratories, where he led a multi-site, multidisciplinary team developing innovative approaches to identify therapies for cancer and immune diseases. Dr. Haining was elected into the American Society for Clinical Investigation, and received the Presidential Early Career Award for Science and Engineering.
Ira Mellman, Genentech
Human cells have been successfully used as treatment for blood cancers for decades but translating the promise to cell-based treatment for solid tumors has been slow. The advent of gene-editing techniques such as CRISPR, coupled with advances in our understanding of immunology and optimization of growing, manufacturing, transporting, storing, and handling specialized biological samples and materials is transforming the cell therapy field. We will hear in this session about some of the most promising work in the field, as well as the challenges in overcoming resistance